News Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
8.04 ^USD	-0.99%		-2.55%	-20.08%

Apr. 18	Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	CI
Apr. 18	Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Chief Financial Officer, Effective May 3, 2024	Apr. 18	CI
Vir Biotechnology, Inc. Announces Stepping Down of Sung Lee as Executive Vice President, effective May 3, 2024	Apr. 18	CI
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors	Apr. 18	BU
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024	Apr. 11	BU
Brii Biosciences Provides Corporate Update and Reports Full-Year 2023 Financial Results	Mar. 25	AQ
Transcript : Vir Biotechnology, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 07:30 AM	Mar. 13
Vir Biotechnology Completes Enrollment in Phase 2 Chronic Hepatitis Delta Trial Ahead of Schedule	Mar. 05	MT
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	Mar. 05	BU
Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule	Mar. 05	CI
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences	Feb. 26	AQ
Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences	Feb. 23	BU
Vir Biotechnology's Q4 Loss Widens, Revenue Declines	Feb. 23	MT
Vir Biotechnology, GSK Terminate Collaboration on Flu	Feb. 22	DJ
Transcript : Vir Biotechnology, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Earnings Flash (VIR) VIR BIOTECHNOLOGY Reports Q4 Revenue $16.8M, vs. Street Est of $6.55M	Feb. 22	MT
Vir Biotechnology, Inc. and Glaxo Wellcome UK Limited Mutually Agrees to Terminate Collaboration on the Influenza Program Under the DCA	Feb. 22	CI
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 22	BU
Vir Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 22	CI
Vir Biotechnology Announces Dr. Phil Pang Will Step Down as Chief Medical Officer	Feb. 20	BU
Vir Biotechnology, Inc. Announces Phil Pang Will Step Down as Chief Medical Officer	Feb. 20	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Vir Biotechnology, Inc.

Equities

VIR

US92764N1028

Summary

Filters